Optimization of medical care for patients with hepatic cirrhosis and analysis of typical mistakes in their management tactics
- Autores: Korochanskaya N.V.1,2, Durleshter V.M1,2, Kovalevskaya O.V2, Serikova S.N1,2, Basenko M.A1
-
Afiliações:
- Kuban State Medical University
- Regional Clinical Hospital № 2
- Edição: Volume 27, Nº 2 (2020)
- Páginas: 45-49
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312507
- DOI: https://doi.org/10.18565/pharmateca.2020.2.45-49
- ID: 312507
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Natalia Korochanskaya
Kuban State Medical University; Regional Clinical Hospital № 2
Email: nvk-gastro@mail.ru
Dr. Sci. (Med.), Head of the astroenterological Center, City Clinical Hospital № 2; Professor at the Department of Surgery № 3 FATPRS, Kuban State Medical University Krasnodar, Russia
V. Durleshter
Kuban State Medical University; Regional Clinical Hospital № 2Department of Surgery № 3 FATPRS Krasnodar, Russia
O. Kovalevskaya
Regional Clinical Hospital № 2Krasnodar, Russia
S. Serikova
Kuban State Medical University; Regional Clinical Hospital № 2Department of Surgery № 3 FATPRS Krasnodar, Russia
M. Basenko
Kuban State Medical UniversityKrasnodar, Russia
Bibliografia
- Backus L.I., Boothroyd D.B., Phillips B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-16. doi: 10.1016/j.cgh.2011.03.004.
- Kanwal F., Kramer J., Asch S.M., et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996-1005. Doi: 10.1053/j. gastro.2017.06.012.
- Liaw Y.F, Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31. doi: 10.1056/NEJMoa033364.
- Fuster D., Samet J.H. Alcohol use in patients with chronic liver disease. N Engl J Med. 2018;379(26):2579. Doi: 10.1056/ NEJMc1814129.
- Kanwal F.,Volk M., Singal A., et al. Improving qualityof health care for patients with cirrhosis. Gastroenterology 2014;147:1204-47. doi: 10.1053/j.gastro.2014.10.029.
- Gins P., Quintero E., Arroyo V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7(1):122-28. Doi: 10.1002/ hep.1840070124.
- DAmico G., Pasta L., Morabito A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180-93. doi: 10.1111/apt.12721.
- DAmico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-31. Doi: 10.1016/j. jhep.2005.10.013
- Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печении Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологиии, гепатологии и колопроктолоогии. 2016;26(4):71-102.
- Iwasa M., Iwata K., Hara N., et al. Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis. Nutrition. 2013;29(11-12):1418-21. Doi: 10.1016/]. nut.2013.05.016.
- Plank L.D., Gane E.J., Peng S., et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557-66. doi: 10.1002/hep.22367.
- Gluud L.L., Krag A. Banding ligation versus betablockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev. 2012;(8):CD004544. doi: 10.1002/14651858. CD004544.pub2.
- Ge P.S., Runyon B.A. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(21):2104-105. doi: 10.1056/NEJMc1612334.
- Alberino F., Gatta A., Amodio P., et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17(6):445-50. doi: 10.1016/s0899-9007(01)00521-4
- Montano-Loza A.J., Meza-Junco J., Prado C.M., et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166- 73. 173.e1. Doi: 10.1016/]. cgh.2011.08.028.
- Merli M., Lucidi C., Giannelli V., et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979-85. Doi: 10.1016/j. cgh.2010.06.024
- Merli M., Giusto M., Lucidi C., et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis. 2013;28(2):281-84. doi: 10.1007/s11011-012-9365-z.
- Huisman E.J., Trip E.J., Siersema P.D., et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol. 2011;23(11):982-89. Doi: 10.1097/ MEG.0b013e32834aa4bb.
- Merli M., Berzigotti A., Zelber-Sagi S., et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172-93. doi: 10.1016/j.jhep.2018.06.024.
- Berzigotti A., Saran U., Dufour J.F. Physical activity and liver diseases. Hepatology 2016;63(3):1026-40. doi: 10.1002/hep.28132
- European Association for the Study of the Liver; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 2018;69:406-60. doi: 10.1016/j.jhep.2018.03.024.
- Tsien C.D., Rabie R., Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131-37. doi: 10.1136/gutjnl-2011-301255.
- Garcia-Tsao G., Abraldes J.G., Berzigotti A., Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-35. doi: 10.1002/hep.28906.
- Pagliaro L., D'Amico G., Pasta L., et al. Portal hypertension in cirrhosis: natural history. In: Bosch J, Groszmann RJ, eds. Portal Hypertension: Pathophysiology and Treatment. Oxford, UK: Blackwell Scientific. 1994. P 72-92.